Computational and in vitro studies on the inhibitory effects of herbal compounds on human cytochrome P450 1A2

References

• Becquemont L, Ragueneau I, Le Bot MA, Riche C, Funck-Brentano C, Jaillon P. (1997). Influence of the CYP1A2 inhibitor fluvoxamine on tacrine pharmacokinetics in humans. Clin Pharmacol Ther 61:619–627.
   PubMed Web of Science ®Google Scholar
• Becquemont L, Ragueneau I, Le Bot MA, Riche C, Funck-Brentano C, Jaillon P. (1997). Influence of the CYP1A2 inhibitor fluvoxamine on tacrine pharmacokinetics in humans. Clin Pharmacol Ther 61:619–627.
   PubMed Web of Science ®Google Scholar
• Burke MD, Thompson S, Weaver RJ, Wolf CR, Mayer RT. (1994). Cytochrome P450 specificities of alkoxyresorufin O-dealkylation in human and rat liver. Biochem Pharmacol 48:923–936.
   PubMed Web of Science ®Google Scholar
• Burton J, Ijjaali I, Barberan O, Petitet F, Vercauteren DP, Michel A. (2006). Recursive partitioning for the prediction of cytochromes P450 2D6 and 1A2 inhibition: Importance of the quality of the dataset. J Med Chem 49:6231–6240.
   PubMed Web of Science ®Google Scholar
• Chang TK, Waxman DJ. (2006). Enzymatic analysis of cDNA-expressed human CYP1A1, CYP1A2, and CYP1B1 with 7-ethoxyresorufin as substrate. Methods Mol Biol 320:85–90.
   PubMedGoogle Scholar
• Cho US, Park EY, Dong MS, Park BS, Kim K, Kim KH. (2003). Tight-binding inhibition by alpha-naphthoflavone of human cytochrome P450 1A2. Biochim Biophys Acta 1648:195–202.
   PubMed Web of Science ®Google Scholar
• Chohan KK, Paine SW, Mistry J, Barton P, Davis AM. (2005). A rapid computational filter for cytochrome P450 1A2 inhibition potential of compound libraries. J Med Chem 48:5154–5161.
   PubMed Web of Science ®Google Scholar
• Chow HH, Garland LL, Hsu CH, Vining DR, Chew WM, Miller JA, Perloff M, Crowell JA, Alberts DS. (2010). Resveratrol modulates drug- and carcinogen-metabolizing enzymes in a healthy volunteer study. Cancer Prev Res (Phila) 3:1168–1175.
   PubMed Web of Science ®Google Scholar
• Crespi CL, Stresser DM. (2000). Fluorometric screening for metabolism-based drug–drug interactions. J Pharmacol Toxicol Methods 44:325–331.
   PubMed Web of Science ®Google Scholar
• de Graaf C, Vermeulen NP, Feenstra KA. (2005). Cytochrome p450 in silico: An integrative modeling approach. J Med Chem 48:2725–2755.
   PubMed Web of Science ®Google Scholar
• de Groot MJ, Kirton SB, Sutcliffe MJ. (2004). In silico methods for predicting ligand binding determinants of cytochromes P450. Curr Top Med Chem 4:1803–1824.
   PubMed Web of Science ®Google Scholar
• De Rienzo F, Fanelli F, Menziani MC, De Benedetti PG. (2000). Theoretical investigation of substrate specificity for cytochromes P450 IA2, P450 IID6 and P450 IIIA4. J Comput Aided Mol Des 14:93–116.
   PubMed Web of Science ®Google Scholar
• Don MJ, Lewis DF, Wang SY, Tsai MW, Ueng YF. (2003). Effect of structural modification on the inhibitory selectivity of rutaecarpine derivatives on human CYP1A1, CYP1A2, and CYP1B1. Bioorg Med Chem Lett 13:2535–2538.
   PubMed Web of Science ®Google Scholar
• Fuhr U, Strobl G, Manaut F, Anders EM, Sörgel F, Lopez-de-Brinas E, Chu DT, Pernet AG, Mahr G, Sanz F. (1993). Quinolone antibacterial agents: Relationship between structure and in vitro inhibition of the human cytochrome P450 isoform CYP1A2. Mol Pharmacol 43:191–199.
   PubMed Web of Science ®Google Scholar
• Gerber NC, Sligar SG. (1994). A role for Asp-251 in cytochrome P-450cam oxygen activation. J Biol Chem 269:4260–4266.
   PubMed Web of Science ®Google Scholar
• Gleeson MP. (2008). Generation of a set of simple, interpretable ADMET rules of thumb. J Med Chem 51:817–834.
   PubMed Web of Science ®Google Scholar
• Granfors MT, Backman JT, Neuvonen M, Neuvonen PJ. (2004). Ciprofloxacin greatly increases concentrations and hypotensive effect of tizanidine by inhibiting its cytochrome P450 1A2-mediated presystemic metabolism. Clin Pharmacol Ther 76:598–606.
   PubMed Web of Science ®Google Scholar
• Guengerich FP. (2006). Cytochrome P450s and other enzymes in drug metabolism and toxicity. AAPS J 8:E101–E111.
   PubMed Web of Science ®Google Scholar
• Gunther S, Patterson RE, Kristal AR, Stratton KL, White E. (2004). Demographic and health-related correlates of herbal and specialty supplement use. J Am Diet Assoc 104:27–34.
   PubMed Web of Science ®Google Scholar
• Hadjokas NE, Dai R, Friedman FK, Spence MJ, Cusack BJ, Vestal RE, Ma Y. (2002). Arginine to lysine 108 substitution in recombinant CYP1A2 abolishes methoxyresorufin metabolism in lymphoblastoid cells. Br J Pharmacol 136:347–352.
   PubMed Web of Science ®Google Scholar
• Harris DL. (2004). In silico predictive metabolism: A structural/electronic filter method. Curr Opin Drug Discov Devel 7:43–48.
   PubMedGoogle Scholar
• Hendrychová T, Anzenbacherová E, Hudecek J, Skopalík J, Lange R, Hildebrandt P, Otyepka M, Anzenbacher P. (2011). Flexibility of human cytochrome P450 enzymes: Molecular dynamics and spectroscopy reveal important function-related variations. Biochim Biophys Acta 1814:58–68.
   PubMed Web of Science ®Google Scholar
• Hu Z, Yang X, Ho PC, Chan SY, Heng PW, Chan E, Duan W, Koh HL, Zhou S. (2005). Herb-drug interactions: A literature review. Drugs 65:1239–1282.
   PubMed Web of Science ®Google Scholar
• Huang Q, Szklarz GD. (2010). Significant increase in phenacetin oxidation on L382V substitution in human cytochrome P450 1A2. Drug Metab Dispos 38:1039–1045.
   PubMed Web of Science ®Google Scholar
• Hutter MC. (2009). In silico prediction of drug properties. Curr Med Chem 16:189–202.
   PubMed Web of Science ®Google Scholar
• Ikeya K, Jaiswal AK, Owens RA, Jones JE, Nebert DW, Kimura S. (1989). Human CYP1A2: Sequence, gene structure, comparison with the mouse and rat orthologous gene, and differences in liver 1A2 mRNA expression. Mol Endocrinol 3:1399–1408.
   PubMed Web of Science ®Google Scholar
• Iori F, da Fonseca R, Ramos MJ, Menziani MC. (2005). Theoretical quantitative structure-activity relationships of flavone ligands interacting with cytochrome P450 1A1 and 1A2 isozymes. Bioorg Med Chem 13:4366–4374.
   PubMed Web of Science ®Google Scholar
• Kim D, Guengerich FP. (2004a). Enhancement of 7-methoxyresorufin O-demethylation activity of human cytochrome P450 1A2 by molecular breeding. Arch Biochem Biophys 432:102–108.
   PubMed Web of Science ®Google Scholar
• Kim D, Guengerich FP. (2004b). Selection of human cytochrome P450 1A2 mutants with enhanced catalytic activity for heterocyclic amine N-hydroxylation. Biochemistry 43:981–988.
   PubMed Web of Science ®Google Scholar
• Klepser TB, Doucette WR, Horton MR, Buys LM, Ernst ME, Ford JK, Hoehns JD, Kautzman HA, Logemann CD, Swegle JM, Ritho M, Klepser ME. (2000). Assessment of patients’ perceptions and beliefs regarding herbal therapies. Pharmacotherapy 20:83–87.
   PubMed Web of Science ®Google Scholar
• Korhonen LE, Rahnasto M, Mähönen NJ, Wittekindt C, Poso A, Juvonen RO, Raunio H. (2005). Predictive three-dimensional quantitative structure-activity relationship of cytochrome P450 1A2 inhibitors. J Med Chem 48:3808–3815.
   PubMed Web of Science ®Google Scholar
• Krainev AG, Shimizu T, Hiroya K, Hatano M. (1992). Effect of mutations at Lys250, Arg251, and Lys253 of cytochrome P450 1A2 on the catalytic activities and the bindings of bifunctional axial ligands. Arch Biochem Biophys 298:198–203.
   PubMed Web of Science ®Google Scholar
• Krejsa CM, Horvath D, Rogalski SL, Penzotti JE, Mao B, Barbosa F, Migeon JC. (2003). Predicting ADME properties and side effects: The BioPrint approach. Curr Opin Drug Discov Devel 6:470–480.
   PubMed Web of Science ®Google Scholar
• Lee H, Yeom H, Kim YG, Yoon CN, Jin C, Choi JS, Kim BR, Kim DH. (1998). Structure-related inhibition of human hepatic caffeine N3-demethylation by naturally occurring flavonoids. Biochem Pharmacol 55:1369–1375.
   PubMed Web of Science ®Google Scholar
• Lewis DF. (1999). Homology modelling of human cytochromes P450 involved in xenobiotic metabolism and rationalization of substrate selectivity. Exp Toxicol Pathol 51:369–374.
   PubMed Web of Science ®Google Scholar
• Lewis DF. (2000). On the recognition of mammalian microsomal cytochrome P450 substrates and their characteristics: Towards the prediction of human p450 substrate specificity and metabolism. Biochem Pharmacol 60:293–306.
   PubMed Web of Science ®Google Scholar
• Lewis DF, Lake BG. (1996). Molecular modelling of CYP1A subfamily members based on an alignment with CYP102: Rationalization of CYP1A substrate specificity in terms of active site amino acid residues. Xenobiotica 26:723–753.
   PubMed Web of Science ®Google Scholar
• Lewis DF, Lake BG, Dickins M, Ueng YF, Goldfarb PS. (2003). Homology modelling of human CYP1A2 based on the CYP2C5 crystallographic template structure. Xenobiotica 33:239–254.
   PubMed Web of Science ®Google Scholar
• Lewis DF, Lake BG, George SG, Dickins M, Eddershaw PJ, Tarbit MH, Beresford AP, Goldfarb PS, Guengerich FP. (1999). Molecular modelling of CYP1 family enzymes CYP1A1, CYP1A2, CYP1A6 and CYP1B1 based on sequence homology with CYP102. Toxicology 139:53–79.
   PubMed Web of Science ®Google Scholar
• Lewis DF, Dickins M. (2001). Quantitative structure-activity relationships (QSARs) within series of inhibitors for mammalian cytochromes P450 (CYPs). J Enzym Inhib 16:321–330.
   PubMed Web of Science ®Google Scholar
• Liu J, Ericksen SS, Sivaneri M, Besspiata D, Fisher CW, Szklarz GD. (2004). The effect of reciprocal active site mutations in human cytochromes P450 1A1 and 1A2 on alkoxyresorufin metabolism. Arch Biochem Biophys 424:33–43.
   PubMed Web of Science ®Google Scholar
• Lozano JJ, López-de-Briñas E, Centeno NB, Guigó R, Sanz F. (1997). Three-dimensional modelling of human cytochrome P450 1A2 and its interaction with caffeine and MeIQ. J Comput Aided Mol Des 11:395–408.
   PubMed Web of Science ®Google Scholar
• Lozano JJ, Pastor M, Cruciani G, Gaedt K, Centeno NB, Gago F, Sanz F. (2000). 3D-QSAR methods on the basis of ligand-receptor complexes. Application of COMBINE and GRID/GOLPE methodologies to a series of CYP1A2 ligands. J Comput Aided Mol Des 14:341–353.
   PubMed Web of Science ®Google Scholar
• Mehta DH, Gardiner PM, Phillips RS, McCarthy EP. (2008). Herbal and dietary supplement disclosure to health care providers by individuals with chronic conditions. J Altern Complement Med 14:1263–1269.
   PubMed Web of Science ®Google Scholar
• Morris GM, Goodsell DS, Halliday RS, Huey R, Hart WE, Belew RK, Olson AJ. (1998). Automated docking using a Lamarckian genetic algorithm and and empirical binding free energy function. J Comput Chem 19:1639–1662.
   Google Scholar
• Murayama N, Soyama A, Saito Y, Nakajima Y, Komamura K, Ueno K, Kamakura S, Kitakaze M, Kimura H, Goto Y, Saitoh O, Katoh M, Ohnuma T, Kawai M, Sugai K, Ohtsuki T, Suzuki C, Minami N, Ozawa S, Sawada J. (2004). Six novel nonsynonymous CYP1A2 gene polymorphisms: Catalytic activities of the naturally occurring variant enzymes. J Pharmacol Exp Ther 308:300–306.
   PubMed Web of Science ®Google Scholar
• Nakajima M, Yoshida R, Shimada N, Yamazaki H, Yokoi T. (2001). Inhibition and inactivation of human cytochrome P450 isoforms by phenethyl isothiocyanate. Drug Metab Dispos 29:1110–1113.
   PubMed Web of Science ®Google Scholar
• Nebert DW, Russell DW. (2002). Clinical importance of the cytochromes P450. Lancet 360:1155–1162.
   PubMed Web of Science ®Google Scholar
• Norinder U. (2005). In silico modelling of ADMET-a minireview of work from 2000 to 2004. SAR QSAR Environ Res 16:1–11.
   PubMed Web of Science ®Google Scholar
• Parikh A, Josephy PD, Guengerich FP. (1999). Selection and characterization of human cytochrome P450 1A2 mutants with altered catalytic properties. Biochemistry 38:5283–5289.
   PubMed Web of Science ®Google Scholar
• Paxton JW, Kestell P, Chiang D, Zhou S, Lewis DF. (2005). Inhibition of human CYP1A2 oxidation of 5,6-dimethyl-xanthenone-4-acetic acid by acridines: A molecular modelling study. Clin Exp Pharmacol Physiol 32:633–639.
   PubMed Web of Science ®Google Scholar
• Poulos TL, Finzel BC, Howard AJ. (1987). High-resolution crystal structure of cytochrome P450cam. J Mol Biol 195:687–700.
   PubMed Web of Science ®Google Scholar
• Qiu F, Zhang R, Sun J, Jiye A, Hao H, Peng Y, Ai H, Wang G. (2008). Inhibitory effects of seven components of danshen extract on catalytic activity of cytochrome P450 enzyme in human liver microsomes. Drug Metab Dispos 36:1308–1314.
   PubMed Web of Science ®Google Scholar
• Rowland P, Blaney FE, Smyth MG, Jones JJ, Leydon VR, Oxbrow AK, Lewis CJ, Tennant MG, Modi S, Eggleston DS, Chenery RJ, Bridges AM. (2006). Crystal structure of human cytochrome P450 2D6. J Biol Chem 281:7614–7622.
   PubMed Web of Science ®Google Scholar
• Roy K, Roy PP. (2008). Comparative QSAR studies of CYP1A2 inhibitor flavonoids using 2D and 3D descriptors. Chem Biol Drug Des 72:370–382.
   PubMed Web of Science ®Google Scholar
• Sansen S, Yano JK, Reynald RL, Schoch GA, Griffin KJ, Stout CD, Johnson EF. (2007). Adaptations for the oxidation of polycyclic aromatic hydrocarbons exhibited by the structure of human P450 1A2. J Biol Chem 282:14348–14355.
   PubMed Web of Science ®Google Scholar
• Schoch GA, Yano JK, Wester MR, Griffin KJ, Stout CD, Johnson EF. (2004). Structure of human microsomal cytochrome P450 2C8. Evidence for a peripheral fatty acid binding site. J Biol Chem 279:9497–9503.
   PubMed Web of Science ®Google Scholar
• Shimada T, Yamazaki H, Foroozesh M, Hopkins NE, Alworth WL, Guengerich FP. (1998). Selectivity of polycyclic inhibitors for human cytochrome P450s 1A1, 1A2, and 1B1. Chem Res Toxicol 11:1048–1056.
   PubMed Web of Science ®Google Scholar
• Strushkevich N, Usanov SA, Plotnikov AN, Jones G, Park HW. (2008). Structural analysis of CYP2R1 in complex with vitamin D3. J Mol Biol 380:95–106.
   PubMed Web of Science ®Google Scholar
• Thelingwani RS, Zvada SP, Dolgos H, Ungell AL, Masimirembwa CM. (2009). In vitro and in silico identification and characterization of thiabendazole as a mechanism-based inhibitor of CYP1A2 and simulation of possible pharmacokinetic drug-drug interactions. Drug Metab Dispos 37:1286–1294.
   PubMed Web of Science ®Google Scholar
• Tuck SF, Hiroya K, Shimizu T, Hatano M, Ortiz de Montellano PR. (1993). The cytochrome P450 1A2 active site: Topology and perturbations caused by glutamic acid-318 and threonine-319 mutations. Biochemistry 32:2548–2553.
   PubMed Web of Science ®Google Scholar
• Ueng YF, Jan WC, Lin LC, Chen TL, Guengerich FP, Chen CF. (2002). The alkaloid rutaecarpine is a selective inhibitor of cytochrome P450 1A in mouse and human liver microsomes. Drug Metab Dispos 30:349–353.
   PubMed Web of Science ®Google Scholar
• Wallace AC, Laskowski RA, Thornton JM. (1995). LIGPLOT: A program to generate schematic diagrams of protein-ligand interactions. Protein Eng 8:127–134.
   PubMedGoogle Scholar
• Williams PA, Cosme J, Ward A, Angove HC, Matak Vinkovic D, Jhoti H. (2003). Crystal structure of human cytochrome P450 2C9 with bound warfarin. Nature 424:464–468.
   PubMed Web of Science ®Google Scholar
• Wilson AG, White AC, Mueller RA. (2003). Role of predictive metabolism and toxicity modeling in drug discovery–a summary of some recent advancements. Curr Opin Drug Discov Devel 6:123–128.
   PubMedGoogle Scholar
• Yanagita K, Sagami I, Daff S, Shimizu T. (1998). Marked enhancement in the reductive dehalogenation of hexachloroethane by a Thr319Ala mutation of cytochrome P450 1A2. Biochem Biophys Res Commun 249:678–682.
   PubMed Web of Science ®Google Scholar
• Yang XX, Hu ZP, Duan W, Zhu YZ, Zhou SF. (2006). Drug-herb interactions: Eliminating toxicity with hard drug design. Curr Pharm Des 12:4649–4664.
   PubMed Web of Science ®Google Scholar
• Yano JK, Hsu MH, Griffin KJ, Stout CD, Johnson EF. (2005). Structures of human microsomal cytochrome P450 2A6 complexed with coumarin and methoxsalen. Nat Struct Mol Biol 12:822–823.
   PubMed Web of Science ®Google Scholar
• Yano JK, Wester MR, Schoch GA, Griffin KJ, Stout CD, Johnson EF. (2004). The structure of human microsomal cytochrome P450 3A4 determined by X-ray crystallography to 2.05-A resolution. J Biol Chem 279:38091–38094.
   PubMed Web of Science ®Google Scholar
• Yun CH, Miller GP, Guengerich FP. (2000). Rate-determining steps in phenacetin oxidations by human cytochrome P450 1A2 and selected mutants. Biochemistry 39:11319–11329.
   PubMed Web of Science ®Google Scholar
• Zhou H, Josephy PD, Kim D, Guengerich FP. (2004a). Functional characterization of four allelic variants of human cytochrome P450 1A2. Arch Biochem Biophys 422:23–30.
   PubMed Web of Science ®Google Scholar
• Zhou S, Chan E, Li X, Huang M. (2005a). Clinical outcomes and management of mechanism-based inhibition of cytochrome P450 3A4. Ther Clin Risk Manag 1:3–13.
   PubMedGoogle Scholar
• Zhou S, Chan E, Lim LY, Boelsterli UA, Li SC, Wang J, Zhang Q, Huang M, Xu A. (2004b). Therapeutic drugs that behave as mechanism-based inhibitors of cytochrome P450 3A4. Curr Drug Metab 5:415–442.
   PubMed Web of Science ®Google Scholar
• Zhou S, Gao Y, Jiang W, Huang M, Xu A, Paxton JW. (2003). Interactions of herbs with cytochrome P450. Drug Metab Rev 35:35–98.
   PubMed Web of Science ®Google Scholar
• Zhou S, Yung Chan S, Cher Goh B, Chan E, Duan W, Huang M, McLeod HL. (2005b). Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs. Clin Pharmacokinet 44:279–304.
   PubMed Web of Science ®Google Scholar
• Zhou SF, Chan E, Zhou ZW, Xue CC, Lai X, Duan W. (2009a). Insights into the structure, function, and regulation of human cytochrome P450 1A2. Curr Drug Metab 10:713–729.
   PubMed Web of Science ®Google Scholar
• Zhou SF, Wang B, Yang LP, Liu JP. (2010). Structure, function, regulation and polymorphism and the clinical significance of human cytochrome P450 1A2. Drug Metab Rev 42:268–354.
   PubMed Web of Science ®Google Scholar
• Zhou SF, Yang LP, Zhou ZW, Liu YH, Chan E. (2009b). Insights into the substrate specificity, inhibitors, regulation, and polymorphisms and the clinical impact of human cytochrome P450 1A2. AAPS J 11:481–494.
   PubMed Web of Science ®Google Scholar
• Zhou SF, Zhou ZW, Li CG, Chen X, Yu X, Xue CC, Herington A. (2007). Identification of drugs that interact with herbs in drug development. Drug Discov Today 12:664–673.
   PubMed Web of Science ®Google Scholar
• Zhou ZW, Zhou SF. (2009). Application of mechanism-based CYP inhibition for predicting drug-drug interactions. Expert Opin Drug Metab Toxicol 5:579–605.
   PubMed Web of Science ®Google Scholar